Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
226.6 USD | +2.74% | +3.51% | +10.32% |
May. 30 | Transcript : Cencora, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 09:20 AM | |
May. 29 | Baird Adjusts Price Target on Cencora to $280 From $277 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.16 for the 2024 fiscal year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.32% | 44.62B | B- | ||
-7.16% | 178B | C+ | ||
-1.23% | 107B | C | ||
-4.86% | 67.04B | A | ||
-4.28% | 47.23B | B- | ||
+8.14% | 42.5B | B+ | ||
+15.53% | 25.22B | A- | ||
-5.88% | 24.14B | A- | ||
-5.38% | 23.69B | B | ||
+1.38% | 22.04B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COR Stock
- Ratings Cencora, Inc.